

Subject Index

- A**
- Abortion
 - induced by prostaglandins 8: 161-163, 164-167
 - Abortion, therapeutic
 - prostaglandins 8: 199-200
 - Acne vulgaris 8: 217-223
 - pathogenesis 8: 217
 - pregnancy 8: 218
 - treatment 8: 217-218
 - acne surgery 8: 222
 - androgen antagonist 8: 218
 - antibacterial agents 8: 221-222
 - corticosteroids 8: 218-219
 - hormones 8: 218-219
 - oestrogens 8: 218
 - physical therapy 8: 219-221
 - β -Adrenergic blocking drugs
 - angina 8: 212-213
 - Adrenocortical function
 - in surgery 8: 234-236
 - Amitriptyline
 - associated with weight gain 8: 229-230
 - side effects 8: 229-230
 - Analgesic nephropathy 8: 238
 - Analgesics
 - ketoprofen 8: 168-175
 - Angina: management 8: 208-216
 - aggravating factors 8: 210-211
 - emotional stress 8: 210
 - strenuous arm activity 8: 211
 - sudden effort 8: 210-211
 - β -blocking drugs 8: 212-213
 - dosage 8: 213
 - precautions 8: 212-213
 - rationale for use 8: 212
 - side effects 8: 213
 - congestive heart failure 8: 216
 - crescendo angina 8: 215
 - diet 8: 209
 - digitalis 8: 213-214
 - diuretics 8: 214
 - drug therapy 8: 211-214
 - education of patients 8: 208
 - glyceryl trinitrate 8: 211
 - intractable angina 8: 215-216
 - isosorbide dinitrate 8: 211
 - physical activity 8: 209-210
 - treatment of arrhythmias 8: 214-215
 - Antacids, liquid
 - evaluation 8: 225-226
 - peptic ulcer therapy 8: 224-225
 - Anti-inflammatory agents
 - ketoprofen 8: 168-175
 - Arrhythmias
 - treatment in angina 8: 214-215
 - Aspirin
 - causing analgesic nephropathy 8: 238

C

 - Contraceptive device
 - prostaglandins 8: 196-197
 - Corticosteroids
 - acne vulgaris 8: 218-219

D

 - Diabetes
 - with myocardial infarction 8: 237
 - Digitalis
 - angina 8: 213-214
 - Drug Interactions
 - ketoprofen 8: 174
 - Drug metabolism
 - modified by intestinal flora 8: 227
 - Drug reactions, adverse
 - amitriptyline 8: 229-230
 - aspirin 8: 238
 - enflurane 8: 230-231
 - ketoprofen 8: 173
 - rifampicin 8: 228-229

E

 - Enflurane
 - in renal disease 8: 230-231
 - side effects 8: 230-231

F

 - Food additives
 - causing purpura 8: 234

G

 - Gastric acid
 - H_2 receptors 8: 226-227
 - Glucocorticoids
 - effect in surgery 8: 234-236
 - Glyceryl trinitrate
 - angina 8: 211

H

 - H_2 -receptors
 - see histamine receptors
 - Hepatitis
 - due to rifampicin 8: 228-229

Hepatotoxicity 8: 228-229

Histamine receptors

gastric acid 8: 226-227

Hydatiform mole

prostaglandins 8: 200

I

Intrauterine device

see contraceptive device

K

Ketoprofen 8: 168-175

animal pharmacology 8: 172-173

clinical trials 8: 169-172

osteoarthritis 8: 171-172

rheumatic diseases 8: 172

rheumatoid arthritis 8: 169-171

dosage 8: 174

drug interactions 8: 174

pharmacokinetics 8: 173

side effects 8: 173

L

Labour, induction

prostaglandins 8: 197-199

M

Metiamide

peptic ulcer 8: 226-227

Micro-organisms, gastro-intestinal

drug metabolism 8: 227

Myocardial infarction

management in diabetes 8: 237

N

Nephrotoxicity

aspirin 8: 238

enflurane 8: 230-231

O

Obstetrics

prostaglandins 8: 161-163

Oestrogens

acne vulgaris 8: 218

Osteoarthritis

therapy

ketoprofen 8: 171-172

P

Peptic ulcer

antacids 8: 224-225

Prostaglandins 8: 176-207

potential clinical uses 8: 200-202

asthma 8: 201

cardiovascular therapeutics 8: 200-201

gastric ulcers 8: 201-202

nasal congestion 8: 202

therapeutic use

obstetrics 8: 161-163, 164-167

Prostaglandins: clinical use 8: 197-200

induction of labour 8: 197-199

prostaglandin E₂ 8: 198

prostaglandin F_{2α} 8: 197-198

safety of prostaglandins 8: 198-199

therapeutic abortion 8: 199-200

cervical dilatation 8: 200

extra-amniotic administration 8: 199-200

intra-amniotic administration 8: 199

missed abortion 8: 200

vaginal administration 8: 200

Prostaglandins: human reproduction 8: 186-197

fertilisation 8: 189

in the female 8: 188-197

in the male 8: 186-188

erection and ejaculation 8: 186-187

male fertility 8: 187-188

intercourse and premature labour 8: 195-196

intrauterine device 8: 196-197

luteolysis 8: 191-194

menstruation 8: 191

ovulation 8: 189-191

physiological roles 8: 186

sperm transport 8: 188-189

spontaneous abortion 8: 194-195

umbilical cord 8: 196

Prostaglandins: pharmacology 8: 181-186

cardiovascular system 8: 182

eye 8: 184

gastrointestinal function 8: 184-185

platelet aggregation 8: 182-183

renal system 8: 182

respiratory system 8: 181

role in inflammation 8: 183-184

Purpura

due to food additives 8: 234

R

H₂-receptors

see histamine receptors

Reproduction, human

role of prostaglandins 8: 186-197

Rheumatoid arthritis

therapy

ketoprofen 8: 169-171

Rifampicin

causing hepatitis 8: 228-229

S

Skin cancer

treatment with urea 8: 233

U

Urea

skin cancer 8: 233

V

Varicose ulcers

eczema 8: 231-233

management 8: 231-233

W

Weight gain

caused by amitriptyline 8: 229-230

Intelligence: Alternative Views of a Paradigm

Editor: K.F. Riegel (Ann Arbor, Mich.)
IV + 132 p., 2 fig., 1973
SFr. 16.- / US \$ 5.00 / DM 15.- / £ 2.40
ISBN 3-8055-1710-6

The present collection of treatises discusses alternative paradigms to that of intelligence and intelligence testing. The old paradigm, according to which man is engaged in a continuous, selfish struggle for his advancement, more in the material than in the intellectual or moral sense, is dead.

Perhaps it continues to serve a useful function by demonstrating its insufficiencies and by helping us to recognize more clearly the directions of our renewed efforts. The contributions included in this collection have parted company with the old paradigm; they aim at providing alternative conceptions of man, society and their development.

The following collection of treatises aims at contributing to the efforts of laying this old body to rest. None of these contributions criticizes particular shortcomings and errors of the old paradigm. They rather elaborate alternatives or critical issues that make these viewpoints diametrically distinct from the old paradigm. In this effort, they cut across several interrelated dimensions.

Fischer promotes a phenomenological approach to psychological development; *Furth* rejects the nature-nurture controversy from a Piagetian point of view; *Lewis* proposes an interaction model of early development; *Overton* questions the additivity assumption of developmental conceptions; *Wohlwill* explores the concept of experience from an ecological point of view; *Elias* elaborates sociocultural implications and directions of behavior genetics. Several contributions engage in cross-cultural and historical comparisons: *Loof* explores issues of social philosophy and educational influences; *Tulkin and Konner* analyze the cultural relativity of intellectual functions; *Weiner* contrasts developmental progression in regard to achievement success and moral efforts.



S. Karger · Basel · München · Paris · London · New York · Sydney

General Information

Publication data: Two volumes of *Drugs* are published annually. Each volume comprises six 80-page issues. Subscription price per volume SFr. 135. - / US \$49.00 / DM128. - / £19.60 including postage. Multiple subscription rates on request. *Drugs* is published by Australasian Drug Information Services Pty. Ltd., 559 Sydney Road, Seaforth, N.S.W. Australia.

Subject index: Each issue has its own comprehensive subject index which is cumulated in issue No. 6 of the second volume in each year.

Editorial matter is prepared by our own professionally qualified editorial staff and by honorary specialist consultants from all fields of medicine. While great care has been taken in compiling and checking the information contained in *Drugs*, the publisher cannot accept any responsibility for errors or omissions. The inclusion or exclusion of any product does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.

Drug nomenclature: Approved names of the British Pharmacopoeia Commission are used throughout the text. When the Commission has not adopted a name for the drug under discussion, the United States Adopted Name (USAN - United States Pharmacopoeial Convention Inc) or the International Non-Proprietary Name (INN - WHO) is used. When available, all three names are given at the head of the evaluations on new drugs and review article sections, and elsewhere in the text as appropriate. Other synonyms (e.g. research code names of new drugs) are also given.

Correspondence: Letters to the editor are welcomed. They should be submitted in duplicate type-written on one side of the paper only and double-spaced with a wide margin. They should be of reasonable length and written in English. Letters will be published if found suitable and will be subject to editorial review and possible abridgement.

Manuscripts: Information on the preparation of manuscripts will be provided to authors.

Copyright: © 1974 ADIS Press. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

Subscription

Subscription orders can be placed with any bookstore or direct with the distributors S. Karger AG, Arnold-Böcklin-Strasse 25, CH-4011 Basel (Switzerland), or else with the following:

Subscription Order Form	
Please enter my subscription for <i>Drugs</i> beginning with	
<input type="checkbox"/> Vol. 1, 1971	<input type="checkbox"/> Vol. 4, 1972 <input type="checkbox"/> Vol. 7, 1974
<input type="checkbox"/> Vol. 2, 1971	<input type="checkbox"/> Vol. 5, 1973 <input type="checkbox"/> Vol. 8, 1974
<input type="checkbox"/> Vol. 3, 1972	<input type="checkbox"/> Vol. 6, 1973
Name _____	
Title _____	
Address _____	
City _____	
State/Zip _____	
Bundesrepublik Deutschland: S. Karger GmbH, Postfach 2, D-8034 Germering/München	
France: S. Karger S.A., 42bis, Bd de La Tour-Maubourg, F-75 Paris 7e	
Great Britain: John Wiley and Sons Ltd., Baffins Lane, Chichester, Sussex	
USA: Albert J. Phiebig Inc., US Representative of S. Karger, P.O. Box 352, White Plains, NY 10602	
Australia: Australasian Drug Information Services Pty. Ltd., Agents in Australasia for S. Karger, P.O. Box 194, Balgowlah/Sydney, NSW 2093	
New Zealand: Australasian Drug Information Services Pty. Ltd., New Zealand Office, P.O. Box 34-030, Birkenhead, Auckland 10	

